Literature DB >> 12467211

Antitumor activity of ER-37328, a novel carbazole topoisomerase II inhibitor.

Katsuji Nakamura1, Hiroyuki Sugumi, Atsumi Yamaguchi, Toshimitsu Uenaka, Yoshihiko Kotake, Toshimi Okada, Junichi Kamata, Jun Niijima, Takeshi Nagasu, Nozomu Koyanagi, Hiroshi Yoshino, Kyosuke Kitoh, Kentaro Yoshimatsu.   

Abstract

DNA topoisomerase II has been shown to be an important therapeutic target in cancer chemotherapy. Here, we describe studies on the antitumor activity of a novel topoisomerase II inhibitor, ER-37328 [12,13-dihydro-5-[2-(dimethylamino)ethyl]-4H-benzo[c]pyrimido[5,6,1- jk]carbazole-4,6,10(5H,11H)-trione hydrochloride]. ER-37328 inhibited topoisomerase II activity at 10 times lower concentration than etoposide in relaxation assay and induced double-strand DNA cleavage within 1 h in murine leukemia P388 cells, in a bell-shaped manner with respect to drug concentration. The maximum amount of DNA cleavage was obtained at 2 microM. Like etoposide, ER-37328 (2 microM) induced topoisomerase II-DNA cross-linking in P388 cells. A spectroscopic study of ER-37328 mixed with DNA demonstrated that ER-37328 has apparent binding activity to DNA. ER-37328 showed potent growth-inhibitory activity against a panel of 21 human cancer cell lines [mean (50% growth-inhibitory concentration) GI50 = 59 nM]. COMPARE analysis according to the National Cancer Institute screening protocol showed that the pattern of the growth-inhibitory effect of ER-37328 was similar to that of etoposide, but different from that of doxorubicin. Studies on etoposide-, amsacrine [4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA)]-, and camptothecin-resistant P388 cell lines showed that: (a) etoposide- and m-AMSA-resistant P388 cell lines were partially resistant to ER-37328 compared with the parental cell line; and (b) a camptothecin-resistant cell line showed no cross-resistance to ER-37328. In addition, ER-37328 overcame P-glycoprotein-mediated resistance. In vivo, ER-37328 produced potent tumor regression of Colon 38 carcinoma inoculated s.c., and its activity was superior to that of etoposide or doxorubicin. These results indicate that ER-37328 inhibits topoisomerase II activity through the formation of topoisomerase II-DNA cleavable complex and has potent antitumor activity both in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12467211

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  4 in total

1.  Antiseptic Effects of New 3'-N-Substituted Carbazole Derivatives In Vitro and In Vivo.

Authors:  Wonhwa Lee; Soyoung Kwak; Eunju Yun; Jee Hyun Lee; MinKyun Na; Gyu-Yong Song; Jong-Sup Bae
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

2.  An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo.

Authors:  Catalin M Lupu; Christoph Eisenbach; Michael A Kuefner; Jan Schmidt; Alaviana D Lupu; Wolfgang Stremmel; Jens Encke
Journal:  J Gastrointest Surg       Date:  2006-05       Impact factor: 3.452

3.  Purification of GidA protein, a novel topoisomerase II inhibitor produced by Streptomyces flavoviridis.

Authors:  Antony K Teresa Infanta S; S D Nisshanthini; M Palaniswamy; J Angayarkanni
Journal:  World J Microbiol Biotechnol       Date:  2013-08-31       Impact factor: 4.253

4.  Discovery of a Carbazole-Derived Lead Drug for Human African Trypanosomiasis.

Authors:  Sarah M Thomas; Andrei Purmal; Michael Pollastri; Kojo Mensa-Wilmot
Journal:  Sci Rep       Date:  2016-08-26       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.